Effects of inhaled fluticasone propionate in children less than 2 years old with recurrent wheezing.

摘要: Our objective was to evaluate the efficacy and safety of two doses fluticasone propionate (FP) in young children with recurrent wheezing risk factors for asthma. study design a randomized, double-blind, placebo-controlled comparison inhaled FP 50 mcg twice daily (FP 100) 125 250), 6 months. Outcome measures included number episodes, days on albuterol, height standard deviation score (height SDS), osteocalcin (OC), bone alkaline phosphatase fraction (AKP), insulin-like growth factor-binding protein 3 (IGFBP-3), serum levels cortisol (SC). subjects were 30 patients, aged 7-24 Mean episodes 6.0 +/- 1.9, 1.9 2.8 1.2; mean albuterol use 24.3 1.3, 6.5 0.8, 9.1 per patient placebo, FP100, FP250 groups, respectively. There significant reduction clinical outcome groups compared placebo (P < 0.01). No correlations found between dosage SDS, OC, AKP, IGFBP-3, SC. In conclusion, asthmatic symptoms, at b.i.d. months significantly improved respiratory symptoms without causing side effects metabolism.